Next-generation CD40 agonists for cancer immunotherapy
(2024) In Expert Opinion on Biological Therapy 24(5). p.351-363- Abstract
Introduction: There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an opportunity to meet this need by promoting priming of tumor-specific T cells and reverting the suppressive tumor microenvironment. This is supported by emerging clinical evidence demonstrating the benefits of immunotherapy with CD40 antibodies in combination with standard of care chemotherapy. Areas covered: This review is focused on the coming wave of next-generation CD40 agonists aiming to improve efficacy and safety, using new approaches and formats beyond monospecific antibodies. Further, the current understanding of the role... (More)
Introduction: There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an opportunity to meet this need by promoting priming of tumor-specific T cells and reverting the suppressive tumor microenvironment. This is supported by emerging clinical evidence demonstrating the benefits of immunotherapy with CD40 antibodies in combination with standard of care chemotherapy. Areas covered: This review is focused on the coming wave of next-generation CD40 agonists aiming to improve efficacy and safety, using new approaches and formats beyond monospecific antibodies. Further, the current understanding of the role of different CD40 expressing immune cell populations in the tumor microenvironment is reviewed. Expert opinion: There are multiple promising next-generation approaches beyond monospecific antibodies targeting CD40 in immuno-oncology. Enhancing efficacy is the most important driver for this development, and approaches that maximize the ability of CD40 to both remodel the tumor microenvironment and boost the anti-tumor T cell response provide great opportunities to benefit cancer patients. Enhanced understanding of the role of different CD40 expressing immune cells in the tumor microenvironment may facilitate more efficient clinical development of these compounds.
(Less)
- author
- Andersson, Hampus LU ; Nyesiga, Barnabas ; Hermodsson, Tova LU ; Enell Smith, Karin ; Hägerbrand, Karin ; Lindstedt, Malin LU and Ellmark, Peter LU
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Antibodies, antigen-presenting cells, bispecific antibodies, CD40, immuno-oncology, tumor-associated antigens
- in
- Expert Opinion on Biological Therapy
- volume
- 24
- issue
- 5
- pages
- 13 pages
- publisher
- Ashley Publications
- external identifiers
-
- scopus:85193961344
- pmid:38764393
- ISSN
- 1471-2598
- DOI
- 10.1080/14712598.2024.2357714
- language
- English
- LU publication?
- yes
- id
- aa8edd8d-eca4-4079-a777-a91e3aec9e57
- date added to LUP
- 2024-06-19 15:03:56
- date last changed
- 2024-06-19 15:04:05
@article{aa8edd8d-eca4-4079-a777-a91e3aec9e57,
abstract = {{<p>Introduction: There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an opportunity to meet this need by promoting priming of tumor-specific T cells and reverting the suppressive tumor microenvironment. This is supported by emerging clinical evidence demonstrating the benefits of immunotherapy with CD40 antibodies in combination with standard of care chemotherapy. Areas covered: This review is focused on the coming wave of next-generation CD40 agonists aiming to improve efficacy and safety, using new approaches and formats beyond monospecific antibodies. Further, the current understanding of the role of different CD40 expressing immune cell populations in the tumor microenvironment is reviewed. Expert opinion: There are multiple promising next-generation approaches beyond monospecific antibodies targeting CD40 in immuno-oncology. Enhancing efficacy is the most important driver for this development, and approaches that maximize the ability of CD40 to both remodel the tumor microenvironment and boost the anti-tumor T cell response provide great opportunities to benefit cancer patients. Enhanced understanding of the role of different CD40 expressing immune cells in the tumor microenvironment may facilitate more efficient clinical development of these compounds.</p>}},
author = {{Andersson, Hampus and Nyesiga, Barnabas and Hermodsson, Tova and Enell Smith, Karin and Hägerbrand, Karin and Lindstedt, Malin and Ellmark, Peter}},
issn = {{1471-2598}},
keywords = {{Antibodies; antigen-presenting cells; bispecific antibodies; CD40; immuno-oncology; tumor-associated antigens}},
language = {{eng}},
number = {{5}},
pages = {{351--363}},
publisher = {{Ashley Publications}},
series = {{Expert Opinion on Biological Therapy}},
title = {{Next-generation CD40 agonists for cancer immunotherapy}},
url = {{http://dx.doi.org/10.1080/14712598.2024.2357714}},
doi = {{10.1080/14712598.2024.2357714}},
volume = {{24}},
year = {{2024}},
}